RU2400232C2 - Комбинации терапевтических агентов для лечения рака - Google Patents
Комбинации терапевтических агентов для лечения рака Download PDFInfo
- Publication number
- RU2400232C2 RU2400232C2 RU2007126978/14A RU2007126978A RU2400232C2 RU 2400232 C2 RU2400232 C2 RU 2400232C2 RU 2007126978/14 A RU2007126978/14 A RU 2007126978/14A RU 2007126978 A RU2007126978 A RU 2007126978A RU 2400232 C2 RU2400232 C2 RU 2400232C2
- Authority
- RU
- Russia
- Prior art keywords
- carcinoma
- tert
- treatment
- butoxyiminomethyl
- camptothecin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 7
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 claims abstract 18
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 10
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims 7
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims 7
- 201000001514 prostate carcinoma Diseases 0.000 claims 5
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- 190000008236 carboplatin Chemical compound 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims 4
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims 4
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 3
- 201000005296 lung carcinoma Diseases 0.000 claims 3
- 210000001672 ovary Anatomy 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- -1 4-ethyl-piperazin-1-ylmethyl Chemical group 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 201000003911 head and neck carcinoma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63643904P | 2004-12-15 | 2004-12-15 | |
| US60/636,439 | 2004-12-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007126978A RU2007126978A (ru) | 2009-01-27 |
| RU2400232C2 true RU2400232C2 (ru) | 2010-09-27 |
Family
ID=36463409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007126978/14A RU2400232C2 (ru) | 2004-12-15 | 2005-12-13 | Комбинации терапевтических агентов для лечения рака |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8975248B2 (enExample) |
| EP (1) | EP1827437B1 (enExample) |
| JP (1) | JP5345323B2 (enExample) |
| KR (1) | KR101367516B1 (enExample) |
| CN (1) | CN101080227B (enExample) |
| AT (1) | ATE531371T1 (enExample) |
| AU (1) | AU2005316652B2 (enExample) |
| BR (1) | BRPI0515774A (enExample) |
| CA (1) | CA2589521C (enExample) |
| CY (1) | CY1112368T1 (enExample) |
| DK (1) | DK1827437T3 (enExample) |
| ES (1) | ES2374828T3 (enExample) |
| HR (1) | HRP20110960T1 (enExample) |
| IL (1) | IL183595A0 (enExample) |
| MA (1) | MA29096B1 (enExample) |
| MX (1) | MX2007007212A (enExample) |
| NO (1) | NO20073552L (enExample) |
| NZ (1) | NZ555370A (enExample) |
| PL (1) | PL1827437T3 (enExample) |
| PT (1) | PT1827437E (enExample) |
| RU (1) | RU2400232C2 (enExample) |
| SI (1) | SI1827437T1 (enExample) |
| TN (1) | TNSN07224A1 (enExample) |
| TW (1) | TW200628151A (enExample) |
| WO (1) | WO2006065780A2 (enExample) |
| ZA (1) | ZA200704701B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122012021252B8 (pt) | 2002-09-06 | 2021-05-25 | Cerulean Pharma Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
| JP5345323B2 (ja) | 2004-12-15 | 2013-11-20 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 癌を処置するための治療剤の組合せ |
| JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
| US9006224B2 (en) * | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
| WO2007094026A1 (en) * | 2006-02-17 | 2007-08-23 | Paolo La Colla | Prophylactic and/or therapeutic treatment of proliferative and conformational diseases |
| EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
| EP2606890A1 (en) * | 2006-04-05 | 2013-06-26 | Novartis AG | Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| WO2007115286A2 (en) * | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CN101837129B (zh) * | 2009-03-19 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| WO2011133479A2 (en) * | 2010-04-19 | 2011-10-27 | Niiki Pharma Inc. | Combination therapy with a proteasome inhibitor and a gallium complex |
| HUE042801T2 (hu) | 2010-11-12 | 2019-07-29 | Pharma Mar Sa | Kombinációs terápia mitózisgátlóval |
| CN102731516B (zh) * | 2011-04-07 | 2014-07-02 | 宁波天衡药业股份有限公司 | 一类具有抗肿瘤活性的喜树碱衍生物 |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| DK3127545T3 (da) * | 2014-04-04 | 2020-08-10 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer |
| WO2016201481A1 (en) | 2015-06-15 | 2016-12-22 | Newsouth Innovations Pty Limited | Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors |
| CN107951888A (zh) * | 2017-12-19 | 2018-04-24 | 天津科技大学 | 阿法替尼与10-羟基喜树碱的药物组合及其应用 |
| CN109091480A (zh) * | 2018-09-19 | 2018-12-28 | 天津科技大学 | 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途 |
| CN113195000A (zh) * | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
| CN111789903A (zh) * | 2019-04-08 | 2020-10-20 | 石小和 | 治疗尿道癌的药物组合物及其制备方法 |
| PH12022551216A1 (en) | 2019-11-21 | 2023-07-17 | Pharma Mar Sa | Methods of treating small cell lung cancer with lurbinectedin formulations |
| CN120695174A (zh) * | 2021-07-01 | 2025-09-26 | 江苏先声生物制药有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
| WO2023165603A1 (en) * | 2022-03-03 | 2023-09-07 | Zai Lab (Shanghai) Co., Ltd. | Dna-pk inhibitor and combination use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2197477C2 (ru) * | 1997-12-05 | 2003-01-27 | АСТРАЗЕНЕКА Ю Кей ЛИМИТЕД | Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08169825A (ja) * | 1994-12-15 | 1996-07-02 | Tanaka Kikinzoku Kogyo Kk | 抗癌剤の併用投与方法及び併用可能な抗癌剤 |
| DE69531722T2 (de) | 1994-11-11 | 2004-07-01 | Debiopharm S.A. | Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| ATE216998T1 (de) * | 1999-03-09 | 2002-05-15 | Sigma Tau Ind Farmaceuti | Camptothecin-derivate mit antitumor-wirkung |
| US7105492B2 (en) | 1999-03-09 | 2006-09-12 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Camptothecin derivatives having antitumor activity |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| WO2003037897A2 (en) | 2001-10-29 | 2003-05-08 | Novartis Ag | Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| EP1545544A2 (en) * | 2002-07-11 | 2005-06-29 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
| AU2004241729A1 (en) * | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| EP1761281A1 (en) * | 2004-06-04 | 2007-03-14 | Pfizer Products Incorporated | Method for treating abnormal cell growth |
| JP5345323B2 (ja) | 2004-12-15 | 2013-11-20 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 癌を処置するための治療剤の組合せ |
| JP4702322B2 (ja) | 2006-12-14 | 2011-06-15 | トヨタ自動車株式会社 | 内燃機関の制御装置 |
-
2005
- 2005-12-13 JP JP2007546818A patent/JP5345323B2/ja not_active Expired - Fee Related
- 2005-12-13 PT PT05853820T patent/PT1827437E/pt unknown
- 2005-12-13 WO PCT/US2005/044993 patent/WO2006065780A2/en not_active Ceased
- 2005-12-13 ES ES05853820T patent/ES2374828T3/es not_active Expired - Lifetime
- 2005-12-13 PL PL05853820T patent/PL1827437T3/pl unknown
- 2005-12-13 BR BRPI0515774-9A patent/BRPI0515774A/pt active Search and Examination
- 2005-12-13 CN CN2005800429798A patent/CN101080227B/zh not_active Expired - Lifetime
- 2005-12-13 MX MX2007007212A patent/MX2007007212A/es active IP Right Grant
- 2005-12-13 EP EP05853820A patent/EP1827437B1/en not_active Expired - Lifetime
- 2005-12-13 AT AT05853820T patent/ATE531371T1/de active
- 2005-12-13 US US11/720,776 patent/US8975248B2/en not_active Expired - Fee Related
- 2005-12-13 AU AU2005316652A patent/AU2005316652B2/en not_active Ceased
- 2005-12-13 CA CA2589521A patent/CA2589521C/en not_active Expired - Fee Related
- 2005-12-13 SI SI200531442T patent/SI1827437T1/sl unknown
- 2005-12-13 HR HR20110960T patent/HRP20110960T1/hr unknown
- 2005-12-13 NZ NZ555370A patent/NZ555370A/en not_active IP Right Cessation
- 2005-12-13 RU RU2007126978/14A patent/RU2400232C2/ru not_active IP Right Cessation
- 2005-12-13 KR KR1020077013401A patent/KR101367516B1/ko not_active Expired - Fee Related
- 2005-12-13 DK DK05853820.8T patent/DK1827437T3/da active
- 2005-12-14 TW TW094144288A patent/TW200628151A/zh unknown
-
2007
- 2007-05-31 IL IL183595A patent/IL183595A0/en unknown
- 2007-06-07 ZA ZA200704701A patent/ZA200704701B/xx unknown
- 2007-06-14 TN TNP2007000224A patent/TNSN07224A1/fr unknown
- 2007-06-18 MA MA29998A patent/MA29096B1/fr unknown
- 2007-07-09 NO NO20073552A patent/NO20073552L/no not_active Application Discontinuation
-
2012
- 2012-01-20 CY CY20121100074T patent/CY1112368T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2197477C2 (ru) * | 1997-12-05 | 2003-01-27 | АСТРАЗЕНЕКА Ю Кей ЛИМИТЕД | Производные адамантана, способ их получения, фармацевтическая композиция на их основе, способ ее получения и способ воздействия на иммуносупрессию |
Non-Patent Citations (1)
| Title |
|---|
| РЛС 2004 ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ. - М.: 2004, подписано в печать 25.07.2003, с.836-837. EFFERTH Т et al. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 24.09.2009], PMID: 15081868 [PubMed - indexed for MEDLINE]. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2400232C2 (ru) | Комбинации терапевтических агентов для лечения рака | |
| Tarantino et al. | Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies | |
| RU2342159C2 (ru) | Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела | |
| Brown et al. | Cisplatin-based chemotherapy of human cancers | |
| Judson et al. | New developments and approaches in the platinum arena | |
| Yafi et al. | First-and second-line therapy for metastatic urothelial carcinoma of the bladder | |
| Zimpfer-Rechner et al. | Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) | |
| MX2007009960A (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| Pereira et al. | Pancreatic cancer: Treatment approaches and trends | |
| RU2011142806A (ru) | Комбинации пентамидина для лечения рака | |
| Wang et al. | Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment | |
| RU2020102713A (ru) | Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата | |
| RU2007104053A (ru) | Лечение рака | |
| Mano et al. | Remaining controversies in the upfront management of advanced ovarian cancer | |
| Petrelli et al. | Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer | |
| FI3773595T3 (fi) | Syöpälääkekoostumuksia yhdistelmähoitoon | |
| Christian et al. | Ovarian cancer chemotherapy | |
| Edelman | Gemcitabine and Carboplatin Regimens in Advanced Non–Small-Cell Lung Cancer: Focus on Randomized Phase III Trials | |
| Kaira et al. | Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer | |
| Baron Esquivias et al. | Cardiac management of Oncology patients | |
| Heys et al. | Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer | |
| Tian et al. | Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer | |
| JP2007523123A5 (enExample) | ||
| Bernier et al. | Docetaxel in the management of patients with head and neck squamous cell carcinoma | |
| Crinò et al. | Gemzar platinum combinations: phase III trials in non-small cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20130225 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201214 |